Marc Lambelet
Overview
Explore the profile of Marc Lambelet including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
151
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pitt B, Agarwal R, Anker S, Rossing P, Ruilope L, Herzog C, et al.
Eur Heart J Cardiovasc Pharmacother
. 2024 Oct;
11(1):10-19.
PMID: 39380152
Aims: Hypokalaemia is associated with cardiovascular events and mortality in patients with chronic kidney disease (CKD). This exploratory FIDELITY analysis, a prespecified pooled patient-dataset from FIDELIO-DKD and FIGARO-DKD, investigated the...
2.
Kirchhof P, Haas S, Amarenco P, Turpie A, Bach M, Lambelet M, et al.
Europace
. 2024 Jun;
26(7).
PMID: 38941511
Aims: Anticoagulation can prevent stroke and prolong lives in patients with atrial fibrillation (AF). However, anticoagulated patients with AF remain at risk of death. The aim of this study was...
3.
Agarwal R, Ruilope L, Ruiz-Hurtado G, Haller H, Schmieder R, Anker S, et al.
J Hypertens
. 2022 Dec;
41(2):295-302.
PMID: 36583355
Objective: Finerenone is a selective nonsteroidal mineralocorticoid receptor antagonist with a short half-life. Its effects on cardiorenal outcomes were thought to be mediated primarily via nonhemodynamic pathways, but office blood...
4.
Filippatos G, Anker S, Pitt B, Rossing P, Joseph A, Kolkhof P, et al.
JACC Heart Fail
. 2022 Nov;
10(11):860-870.
PMID: 36328655
Background: In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and heart failure (HF) increase with decreasing kidney function (estimated glomerular filtration rate [eGFR]) and increasing albuminuria (urine...
5.
Pitt B, Agarwal R, Anker S, Ruilope L, Rossing P, Ahlers C, et al.
JAMA Netw Open
. 2022 Oct;
5(10):e2236123.
PMID: 36287567
Importance: Patients with chronic kidney disease and type 2 diabetes have a higher risk of developing pneumonia as well as an increased risk of severe COVID-19-associated adverse events and mortality....
6.
Rossing P, Agarwal R, Anker S, Filippatos G, Pitt B, Ruilope L, et al.
Diabetes Obes Metab
. 2022 Oct;
25(2):407-416.
PMID: 36193847
Aims: To explore the modifying effect of glucagon-like peptide-1 receptor agonist (GLP-1RA) use on outcomes with finerenone across a wide spectrum of patients with chronic kidney disease (CKD) and type...
7.
Benza R, Farber H, Frost A, Ghofrani H, Corris P, Lambelet M, et al.
Respir Med
. 2022 Mar;
195:106783.
PMID: 35256218
Background: Currently there are no risk assessment recommendations for chronic thromboembolic pulmonary hypertension (CTEPH). The Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) risk score (RRS), developed for...
8.
Benza R, Boucly A, Farber H, Frost A, Ghofrani H, Hoeper M, et al.
J Heart Lung Transplant
. 2021 Dec;
41(3):411-420.
PMID: 34848133
Background: Risk assessment is essential in pulmonary arterial hypertension (PAH) management. We investigated the effect of riociguat on REVEAL Lite 2 score, an abridged version of the REVEAL risk score,...
9.
Benza R, Farber H, Frost A, Ghofrani H, Corris P, Lambelet M, et al.
Int J Cardiol
. 2021 Mar;
332:189-192.
PMID: 33744348
Background: Regular risk assessment is recommended in pulmonary arterial hypertension (PAH) management to improve patient outcomes. The REVEAL risk score (RRS) predicts survival in patients with PAH, including those from...
10.
Camm A, Amarenco P, Haas S, Bach M, Kirchhof P, Kuhls S, et al.
Clin Cardiol
. 2020 Sep;
43(12):1405-1413.
PMID: 32896928
Background: The XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events...